ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Wise, MD
NYU Langone Health
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Davis Comprehensive Cancer Center
Sacramento, California, United States
- Rocky Mountain Cancer Centers Usor
Aurora, Colorado, United States
- Moffitt Cancer Cancer
Tampa, Florida, United States
- Emory University Winship Cancer Institute
Atlanta, Georgia, United States
- the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Chesapeake Urology Research Associates
Towson, Maryland, United States
- Lahey Hospital & Medical Center
Burlington, Massachusetts, United States
- University of Mississippi Medical Center
Jackson, Mississippi, United States
- Xcancer/gu Research Network
Omaha, Nebraska, United States
- Rutgers Cancer Institute
New Brunswick, New Jersey, United States
- New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Columbia University Irving Cancer Center
New York, New York, United States
- Nyu Langone Health, Laura & Isaac Perlmutter Cancer Center
New York, New York, United States
- Unc North Carolina Comprehensive Cancer Care Center
Chapel Hill, North Carolina, United States
- Duke Cancer Center
Durham, North Carolina, United States
- the Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Ohsu Knight Cancer Institute
Portland, Oregon, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
- Virginia Cancer Specialists Usor
Fairfax, Virginia, United States
- Virginia Oncology Associates Usor
Norfolk, Virginia, United States
- Oncology and Hematology Associates of Southwest Virginia Usor
Norton, Virginia, United States
- Uw Carbone Cancer Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Dec 2023
- Primary completion
- 30 Nov 2026
- Completion
- 30 Nov 2027
- Last update posted
- 22 May 2026
- Registered enrollment
- 148
- Registry id
- NCT05682443
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.